It’s much cheaper to develop cancer drugs than pharmaceutical companies claim, say the authors of a new analysis. According to the analysis of R&D costs associated with ten new cancer medicines and subsequent revenue earned, the return on investment is of a magnitude not seen in other industries. The US study found the median R&D cost for ...
Healthy ROI on cancer drugs for pharma
By Mardi Chapman
28 Sep 2017